Last reviewed · How we verify
NCT03244605
Efficacy Study of Comprehensive Rehabilitation Program in Postoperative NSCLC Patients
Phase 3 trial testing Rehabilitation Training in Non-small Cell Lung Cancer in 236 participants. Status unknown.
30 September 2019
Quick facts
| Lead sponsor | Shanghai University of Traditional Chinese Medicine |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 236 |
| Start date | 1 October 2016 |
| Primary completion | 30 September 2019 |
| Estimated completion | 30 December 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Rehabilitation Training
- Rehabilitation Education
- TCM — full drug profile →
- placebo
Conditions studied
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
Sponsor
Shanghai University of Traditional Chinese Medicine
Who can join
Adults 18 to 75, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators performed a multi-centered, randomized, placebo-controlled, prospective clinical trial on the effect of comprehensive rehabilitation program to improve quality of life(QOL) and long-term survival of postoperative patients with early lung cancer. The investigators plan to enroll 236 cases in 3 years (118 cases for rehabilitation training plus traditional Chinese medicine (TCM), 118 cases for rehabilitation education plus placebo), expecting that comprehensive rehabilitation program has a better efficacy on improving QOL and long-term survival.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?
Avancini A, Sartori G, Gkountakos A, Casali M, et al · · 2020 · cited 120× · PMID 32162811 · DOI 10.1634/theoncologist.2019-0463 -
Attempting to Identify Bacterial Allies in Immunotherapy of NSCLC Patients.
Grenda A, Iwan E, Krawczyk P, Frąk M, et al · · 2022 · cited 22× · PMID 36551735 · DOI 10.3390/cancers14246250 -
Dysbiosis of the Gut Microbiome Is Associated With Histopathology of Lung Cancer.
Qin X, Bi L, Yang W, He Y, et al · · 2022 · cited 19× · PMID 35774470 · DOI 10.3389/fmicb.2022.918823
Verify or expand the search:
- PubMed search for NCT03244605
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rehabilitation Training
Trials testing the same drug.
- NCT06040814 — Microbiota, Sarcopenia, and Hepatic Encephalopathy Change in Cirrhotic Patients Before and After Rehabilitation · NA · unknown
- NCT05431010 — Efficacy on Walking Ability of Electroacupuncture Therapy in Elderly Patients With Sarcopenia · NA · recruiting
- NCT03372694 — Efficacy Study of Comprehensive Rehabilitation Program Plus Chemotherapy in Postoperative NSCLC Patients · Phase 3 · unknown
Other recruiting trials for Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
- NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Other Shanghai University of Traditional Chinese Medicine trials
Trials by the same sponsor.
- NCT07331740 — Development and Application of a Parenting Anxiety Intervention Program for Young and Middle-Aged Female Breast Cancer P · NA · not yet recruiting
- NCT07069049 — Electroacupuncture in the Treatment of Patients Undergoing Transperineal Prostate Biopsy Under Local Anesthesia · NA · not yet recruiting
- NCT07245342 — Electroacupuncture for Improving Urinary Incontinence After Radical Prostatectomy · NA · not yet recruiting
- NCT06921512 — TCM Daoyin for Anxiety/Depression: Psychological Effects and Biological Mechanisms · NA · recruiting
- NCT06690606 — EOCRCPred: an AI Model to Predict Survival in EOCRC Patients After Surgery · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03244605 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai University of Traditional Chinese Medicine
- Last refreshed: 12 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03244605.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing